Cellebrite DI Ltd. $CLBT is Voss Capital LP’s 3rd Largest Position

Voss Capital LP boosted its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 18.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 8,050,000 shares of the company’s stock after buying an additional 1,277,300 shares during the period. Cellebrite DI comprises 7.0% of Voss Capital LP’s holdings, making the stock its 3rd biggest position. Voss Capital LP’s holdings in Cellebrite DI were worth $145,142,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of CLBT. Cooper Creek Partners Management LLC purchased a new position in Cellebrite DI during the third quarter valued at $55,999,000. Granahan Investment Management LLC grew its stake in Cellebrite DI by 1,108.5% during the third quarter. Granahan Investment Management LLC now owns 2,629,299 shares of the company’s stock valued at $48,721,000 after acquiring an additional 2,411,726 shares in the last quarter. Capital International Investors purchased a new position in Cellebrite DI during the fourth quarter valued at $41,073,000. Invesco Ltd. grew its stake in Cellebrite DI by 58.6% during the third quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock valued at $103,030,000 after acquiring an additional 2,054,644 shares in the last quarter. Finally, Pertento Partners LLP grew its stake in Cellebrite DI by 57.8% during the third quarter. Pertento Partners LLP now owns 4,648,215 shares of the company’s stock valued at $86,131,000 after acquiring an additional 1,702,574 shares in the last quarter. 45.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. DA Davidson assumed coverage on shares of Cellebrite DI in a research note on Wednesday, May 27th. They set a “buy” rating and a $20.00 target price for the company. Wall Street Zen upgraded shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Finally, Needham & Company LLC lowered their price objective on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.40.

Cellebrite DI Price Performance

CLBT stock opened at $12.84 on Friday. Cellebrite DI Ltd. has a 52 week low of $11.02 and a 52 week high of $19.98. The company has a fifty day simple moving average of $13.23 and a two-hundred day simple moving average of $15.05. The firm has a market capitalization of $3.20 billion, a P/E ratio of 45.86, a price-to-earnings-growth ratio of 1.59 and a beta of 1.17.

Insider Activity

In other news, CRO Marcus Jewell sold 12,658 shares of the firm’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the sale, the executive owned 440,101 shares in the company, valued at approximately $5,620,089.77. This trade represents a 2.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders have sold 13,269 shares of company stock valued at $169,592. 5.70% of the stock is currently owned by company insiders.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.